Company intelligence / Profile preview

3z International

Ownership: Private
Development stage: Other

Overview

3Z Pharmaceuticals has developed a proprietary zebrafish-based screening platform to identify and repurpose small molecule drugs for central nervous system disorders. The company’s approach enables faster drug discovery, particularly for neurological diseases, by leveraging existing safety data from approved drugs. Their lead asset is in ADHD, with additional programs in other CNS indications. They are seeking partners for further development and commercialization.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 3z International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3z International.

Explore the full profile